NAMPT and hyperlipidemia: We minimized confounding factors by excluding subjects with conditions known to affect visfatin (e.g., diabetes, renal or liver failure, untreated hyperlipidemia, hypertension, thyroid dysfunction, recent surgery, or active malignancies other than NETs).